Ticker League

Revenue for Vertex Pharmaceuticals (VRTX)

Latest filings through · Reported

Metric

TTM

$12.26B

YoY change

+9.6%

5Y CAGR

+14.2%

Peak year (2025)

$12.07B

Revenue history chart for Vertex Pharmaceuticals (VRTX) from 1990 to 2025

Latest: $12.07B

Revenue growth chart for Vertex Pharmaceuticals (VRTX) from 1990 to 2025

Latest: +9.6%

Revenue history table for Vertex Pharmaceuticals (VRTX) from 1990 to 2025

  • 2025$12.07B+9.6%
  • 2024$11.02B+11.7%
  • 2023$9.87B+10.5%
  • 2022$8.93B+17.9%
  • 2021$7.57B+22.1%
  • 2020$6.21B+49.1%
  • 2019$4.16B+36.6%
  • 2018$3.05B+22.5%
  • 2017$2.49B+46.2%
  • 2016$1.70B+64.9%
  • 2015$1.03B+77.9%
  • 2014$580.41M-52.1%
  • 2013$1.21B-20.6%
  • 2012$1.53B+8.3%
  • 2011$1.41B+883.9%
  • 2010$143.37M+40.5%
  • 2009$102.05M-41.9%
  • 2008$175.50M-11.8%
  • 2007$199.01M-8.0%
  • 2006$216.36M+34.5%
  • 2005$160.89M+56.6%
  • 2004$102.72M+48.6%
  • 2003$69.14M-57.1%
  • 2002$161.09M-3.8%
  • 2001$167.49M+114.4%
  • 2000$78.13M+26.8%
  • 1999$61.60M+38.7%
  • 1998$44.40M+1.4%
  • 1997$43.80M+229.3%
  • 1996$13.30M-39.8%
  • 1995$22.10M+12.8%
  • 1994$19.60M-29.7%
  • 1993$27.90M+634.2%
  • 1992$3.80M+18.8%
  • 1991$3.20M+39.1%
  • 1990$2.30M—

Revenue values are taken from Vertex Pharmaceuticals's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About Revenue at Vertex Pharmaceuticals (VRTX)

According to Vertex Pharmaceuticals's latest reported financial statements, the company's current revenue (TTM) is $12.26B. Revenue is the total income from selling goods or services before any expenses. Unlike net income (earnings), revenue does not subtract operating costs, taxes, or other charges. Figures are in USD; chart and tables below use historical filings.

Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .

As of the 2025 fiscal year, Vertex Pharmaceuticals (VRTX) reported revenue of $12.07B – grew 9.6% year-over-year.

Through 2020–2025 (5 years), Vertex Pharmaceuticals revenue delivered a +14.2% annualised rate; sustaining 11 straight years of year-over-year growth.

$12.07B stands as the all-time-high annual revenue, posted in 2025, against a low of $2.30M during 1990.

Vertex Pharmaceuticals Revenue by Year

Vertex Pharmaceuticals Revenue 2025: $12.07B

In 2025, Vertex Pharmaceuticals reported revenue of $12.07B, grew 9.6% from 2024. This figure represents the highest annual value in the available history.

Vertex Pharmaceuticals Revenue 2024: $11.02B

Vertex Pharmaceuticals revenue in 2024 was $11.02B, grew 11.7% from 2023.

Vertex Pharmaceuticals Revenue 2023: $9.87B

2023's revenue for Vertex Pharmaceuticals came in at $9.87B, grew 10.5% from 2022.

Vertex Pharmaceuticals Revenue 2022: $8.93B

Vertex Pharmaceuticals posted revenue of $8.93B in 2022, grew 17.9% from 2021.

Vertex Pharmaceuticals Revenue 2021: $7.57B

Vertex Pharmaceuticals revenue in 2021 was $7.57B.

See more financial history for Vertex Pharmaceuticals (VRTX).

Sector peers by Revenue

Healthcare peers of Vertex Pharmaceuticals (VRTX), ranked by their latest revenue

Frequently asked questions

Vertex Pharmaceuticals (VRTX) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation